From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications

References

• Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377(9783):2127–2137.
   PubMed Web of Science ®Google Scholar
• Palazzi C, D’ Angelo S, Lubrano E, et al. Aortic involvement in ankylosing spondylitis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S131–S134.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–783.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009;60:717–727.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25–31.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2011;376:957–970.
   Google Scholar
• Callhoff J, Sieper J, Weiß A, et al. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015;74(6):1241–1248.
   PubMed Web of Science ®Google Scholar
• Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012;71(3):319–326.
   PubMed Web of Science ®Google Scholar
• Spadaro A, Lubrano E, Marchesoni A, et al. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. Rheumatology (Oxford). 2013;52:1914–1919.
   PubMed Web of Science ®Google Scholar
• Perrotta FM, Marchesoni A, Lubrano E. Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol. 2016;43:350–355.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Perrotta FM, Marchesoni A, et al. Remission in non-radiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. J Rheumatol. 2015;42:258–263.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780–789.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Perrotta FM. Secukinumab for ankylosing spondylitis and psoriatic arthritis. Ther Clin Risk Manag. 2016;12:1587–1592.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020–1026.
   PubMed Web of Science ®Google Scholar
• Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44:1876–1886.
   PubMed Web of Science ®Google Scholar
• Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:18–24.
   PubMed Web of Science ®Google Scholar
• Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70(1):47–53.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2017. DOI:10.1136/annrheumdis-2017-211734.
   Web of Science ®Google Scholar
• Gratacos J, Moreno Martinez-Losa M, Font P, et al. Etoricoxib in ankylosing spondylitis: is there a role for active patients refractory to traditional NSAIDs? Clin Exp Rheumatol. 2016;34:94–99.
   PubMed Web of Science ®Google Scholar
• Sieper J, Rudwaleit M, Lenaerts J, et al. Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics. Rheumatology (Oxford). 2016;55(11):1946–1953.
   PubMed Web of Science ®Google Scholar
• Song IH, Hermann KG, Haibel H, et al. Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial. J Rheumatol. 2014;41(10):2034–2040.
   PubMed Web of Science ®Google Scholar
• Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815–822.
   PubMed Web of Science ®Google Scholar
• Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis. 2012 May;71(5):661–667.
   PubMed Web of Science ®Google Scholar
• Sieper J, van der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2015;67(10):2702–2712.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Dougados M, Landewé R, et al. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford). 2017;56(9):1498–1509.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Gensler LS. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2014;28(5):807–818.
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–2548.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Kivitz AJ, Deodhar AA, et al. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol. 2017 May 15. [Epub ahead of print].
   Google Scholar
• Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–1339.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Perrotta FM. Beyond TNF inhibitors: new pathways and emerging treatments for psoriatic arthritis. Drugs. 2016;76:663–673.
   PubMed Web of Science ®Google Scholar
• Schoels MM, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75:811–818.
   PubMed Web of Science ®Google Scholar
• Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70(2):272–277.
   PubMed Web of Science ®Google Scholar
• Helliwell PS, Fitzgerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:986–989.
   PubMed Web of Science ®Google Scholar
• Arends S, Brouwer E, Efde M, et al. Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice. Clin Exp Rheumatol. 2017;35(1):61–68.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Koenig AS, Jones H, et al. Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials. J Rheumatol. 2015;42(8):1418–1426.
   PubMed Web of Science ®Google Scholar
• Vastesaeger N, van der Heijde D, Inman RD, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis. 2011;70(6):973–981.
   PubMed Web of Science ®Google Scholar
• Perrotta FM, Addimanda O, Ramonda R, et al. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs. Reumatismo. 2014;66(3):208–214.
   PubMedGoogle Scholar
• Paramarta JE, De Rycke L, Heijda TF, et al. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis. Ann Rheum Dis. 2013;72:1793–1799.
   PubMed Web of Science ®Google Scholar
• Mease P, Sieper J, Van den Bosch F, et al. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol. 2015;67(4):914–923.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Perrotta FM, Kavanaugh A. An overview of low disease activity and remission in psoriatic arthritis. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S51–S54.
   PubMed Web of Science ®Google Scholar
• Coates LC, Fransen J, Helliwell PS. Defining disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48–53.
   PubMed Web of Science ®Google Scholar
• Coates L, Helliwell P. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res. 2010;62:965–969.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Soriano E, FitzGerald O. Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis? Clin Exp Rheumatol. 2013;31(4 Suppl 78):S54–S58.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Hing EN, Schentag CT, et al. Remission in psoriatic arthritis. J Rheumatol. 2001;28:1045–1048.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Heckaman M, Kary S, et al. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT. J Rheumatol. 2013;40:647–652.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, van der Heijde D, Beutler A, et al. Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res (Hoboken). 2016;68(2):267–274.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48–55.
   PubMed Web of Science ®Google Scholar
• Haddad A, Thavaneswaran A, Arruza IR, et al. Minimal disease activity and anti-TNF Therapy in psoriatic arthritis. Arthritis Care Res (Hoboken). 2015;67:842–847.
   PubMed Web of Science ®Google Scholar
• Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish early psoriatic arthritis register (SwePsA). Ann Rheum Dis. 2014;73:407–413.
   PubMed Web of Science ®Google Scholar
• Van Den Bosch F, Kavanaugh A, Kron M, et al. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations. J Rheumatol. 2015;42:952–959.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Parsons WJ, Perrotta FM. Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors. J Rheumatol. 2016;43:918–923.
   PubMed Web of Science ®Google Scholar
• Nash P, Lubrano E, Cauli A, et al. Updated guidelines for the management of axial disease in psoriatic arthritis. J Rheumatol. 2014;41:2286–2289.
   PubMed Web of Science ®Google Scholar
• Coates LC, Helliwell PS. Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol. 2016;43:371–375.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Perrotta FM. Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol. 2016;43(9):1765–1766.
   PubMed Web of Science ®Google Scholar
• Marin J, Acosta Felquer ML, Ferreyra Garrot L, et al. Patients with psoriatic arthritis fulfilling the minimal disease activity criteria do not have swollen and tender joints, but have active skin. J Rheumatol. 2016;43:907–910.
   PubMedGoogle Scholar
• Lubrano E, De Socio A, Perrotta FM. Comparison of composite indices tailored for psoriatic arthritis treated with csDMARD and bDMARD: a cross-sectional analysis of a longitudinal cohort. J Rheumatol. 2017;44:1159–1164.
   PubMed Web of Science ®Google Scholar
• Rahman P, Zummer M, Bessette L, et al. Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry. BMJ Open. 2017;7(8):e016619.
   PubMed Web of Science ®Google Scholar
• Van Mens LJJ, Turina MC, van de Sande MGH, et al. Residual disease activity in psoriatic arthritis: discordance between the rheumatologist’s opinion and minimal disease activity measurement. Rheumatology (Oxford). 2017. DOI:10.1093/rheumatology/kex183.
   Web of Science ®Google Scholar
• D’Angelo S, Cutro MS, Lubrano E, et al. Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis. Ann Rheum Dis. 2010;69:934–935.
   PubMed Web of Science ®Google Scholar
• Song IH, Althoff CE, Haibel H, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis. 2012;71(7):1212–1215.
   PubMed Web of Science ®Google Scholar
• Almirall M, Salman-Monte TC, Lisbona MP, et al. Dose reduction of biological treatment in patients with axial spondyloarthritis in clinical remission: are there any differences between patients who relapsed and to those who remained in low disease activity? Rheumatol Int. 2015;35(9):1565–1568.
   PubMed Web of Science ®Google Scholar
• Araujo EG, Finzel S, Englbrecht M, et al. High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission. Ann Rheum Dis. 2015;74(4):655–660.
   PubMed Web of Science ®Google Scholar
• Harrold LR, Stolshek BS, Rebello S, et al. Rebound in measures of disease activity and symptoms in corrona registry patients with psoriatic arthritis who discontinue tumor necrosis factor inhibitor therapy after achieving low disease activity. J Rheumatol. 2017. DOI:10.3899/jrheum.161567.
   Google Scholar
• Spadaro A, Punzi L, Marchesoni A, et al. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford). 2010;49(6):1107–1111.
   PubMed Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060–1071.
   PubMed Web of Science ®Google Scholar